Researchers at the Massachusetts Institute of Technology developed a generative artificial intelligence model capable of designing novel antibiotic structures de novo and from chemical fragments. The AI screened over 10 million proposed structures and selected promising candidates, with two dozen undergoing experimental testing. This approach exemplifies AI’s potential to accelerate antibiotic discovery pipelines by proposing innovative molecules that can combat resistant pathogens, a critical need amid rising antimicrobial resistance globally.